Pretzel Therapeutics Receives UK Authorization to Advance PX578 Into Clinical Development
The authorization allows development of PX578 in patients with POLG-mediated primary mitochondrial disorders. The milestone follows U.S. FDA clearance of its investigational new drug application in August.